Q-omics provides the consensus-scored FAM219B profile across patient tissues and cancer cell-line models. FAM219B expression is associated with patient survival in 24 of 34 cancer types, with the highest sampling consensus in COAD. Among the 18 cancer types available for tumor–normal comparison, FAM219B is differentially expressed in 10, with the highest sampling consensus in LIHC. Additionally, FAM219B RNA expression shows 20,766 significant gene co-expression associations, with the highest sampling consensus in ACC. Together, these results highlight COAD, LIHC, and ACC as cancer lineages where FAM219B shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for FAM219B — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes FAM219B survival associations across molecular data types. FAM219B RNA expression shows survival associations in the most cancer types (24), followed by mutation status (2) and mass-spec protein abundance (2). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible FAM219B RNA expression–survival associations across cancer types. High FAM219B expression shows unfavorable associations in COAD, UVM, ACC and LIHC, but favorable associations in KIRC and UCS. The COAD Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify COAD as the clearest survival context for FAM219B RNA expression.
This table summarizes FAM219B tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 10, while mass-spec protein shows differences in 2. The strongest signals are observed in LIHC for RNA and CCRCC for protein.
This table ranks reproducible tumor–normal expression differences for FAM219B. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. FAM219B shows lower tumor expression in LUAD, KICH, BRCA and LUSC and higher tumor expression in LIHC and CHOL. The LIHC box plot shows higher FAM219B RNA expression in tumor versus normal tissue (log2 FC = +0.934, t-test p < 0.001).
This table shows molecular features associated with FAM219B in patient tissues and cancer cell lines. In patient samples, FAM219B shows the broadest associations at the RNA and protein expression levels, with ACC recurring as the lineage with the largest associated feature set. In cancer cell lines, FAM219B RNA and mutation anchors are most strongly linked to RNA-expression features, especially in LUNG_NSCLC_LUAD, while CRISPR and shRNA rows add functional-dependency signals in LIVER and LARGE_INTESTINE.
